NCT07505212

Brief Summary

The goal of this clinical trial is to understand how gallotannin-rich (GT-rich) mangoes can reduce the inflammatory markers in obese individuals in vitro. The study will also seek to explore how gallotannins are metabolized in the gut microbiome. The main questions the research aims to answer are:

  • What is the impact of GT extract from mango and Lactiplantibacillus pentosus supplementation on inflammatory biomarkers in obese individuals?
  • Does the combination of GTs and L. pentosus exhibit synergistic effects in modulating specific microbial taxa associated with obesity and inflammation compared to either intervention alone?
  • Does genetic variation among individuals with obesity account for the ability to metabolize gallotannins? Researchers will compare the effects of GT extract from mango juice, a combination of GT-rich extract, and L. pentosus probiotic supplement on samples (stool) provided by obese individuals, to samples provided by a lean control group to see if gallotannins and gallotannins + probiotic supplementation reduce inflammation in obesity. Participants will
  • Be grouped into 4 treatment groups
  • Mango juice only
  • Mango + L. pentosus
  • L. pentosus only
  • Control (lean individuals)
  • Visit sample collection site one time during the study (week 1)

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 4, 2025

Completed
4 months until next milestone

First Posted

Study publicly available on registry

April 1, 2026

Completed
13 days until next milestone

Study Start

First participant enrolled

April 14, 2026

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Completed
Last Updated

June 9, 2026

Status Verified

April 1, 2026

Enrollment Period

2 months

First QC Date

December 4, 2025

Last Update Submit

June 8, 2026

Conditions

Keywords

Gut microbiomeObesity-related inflammationGallotanninLactiplantibacillus pentosus

Outcome Measures

Primary Outcomes (1)

  • Levels of GT metabolites and short-chain fatty acids (SFCAs) and changes in gut microbiome using HPLC-ESI-MSⁿ and 16s rDNA sequencing, respectively.

    GT metabolites and short-chain fatty acids (SCFAs) will be quantified using HPLC-ESI-MSⁿ, an advanced analytical technique that integrates compound separation, ionization, and structural characterization. In this method, HPLC separates mixture components based on their chemical properties, after which electrospray ionization (ESI) converts analytes into charged ions while preserving their structure. These ions are then subjected to multi-stage mass spectrometry (MSⁿ), enabling successive fragmentation and detailed structural identification of metabolites. Changes in gut microbiome composition will be assessed using 16S rDNA sequencing, a molecular technique that identifies and characterizes bacteria based on the highly conserved 16S ribosomal RNA gene. This involves DNA extraction, PCR amplification of the 16S rRNA gene, sequencing of variable regions, and comparison with reference databases to determine microbial diversity and composition.

    Baseline (for all outcome measures) End of treatment at 12 hours (in vitro assessment)

Study Arms (4)

GT extract + Lactiplantibacillus pentosus arm

ACTIVE COMPARATOR

In this group, stool sample provided by volunteers will be treated with GT extract and L. pentosus.

Dietary Supplement: Gallotannin-rich mangoDietary Supplement: Lactiplantibacillus pentosus (probiotic)

Gallotannin extract from mango only

ACTIVE COMPARATOR

In this group, stool sample provided by volunteers will be treated with GT extract only.

Dietary Supplement: Gallotannin-rich mango

Lactiplantibacillus pentosus supplement arm

ACTIVE COMPARATOR

In this group, stool sample provided by volunteers will be treated with L. pentosus only.

Dietary Supplement: Lactiplantibacillus pentosus (probiotic)

Control group

PLACEBO COMPARATOR
Other: No Treatment Added

Interventions

Gallotannin-rich mangoDIETARY_SUPPLEMENT

This mango is high in polyphenols, specifically hydrolysable tannins, which are easily broken down by microbes in the colon. The metabolites formed can improve the gut microbiome population and also improve immune response.

Also known as: Ataulfo mango
GT extract + Lactiplantibacillus pentosus armGallotannin extract from mango only

Lactiplantibacillus pentosus is a probiotic bacterium that can benefit gut health and may have additional benefits like reducing inflammation

GT extract + Lactiplantibacillus pentosus armLactiplantibacillus pentosus supplement arm

This intervention has no treatment added so as to serve as a control for the other interventions.

Control group

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may not qualify if:

  • Participants with history of acute cardiac events, stroke, or cancer, recurrent hospitalizations, drug treatment of listed conditions within 6 months before study begin, abuse of alcohol/substance, on medications against T2DM or related diseases, smoking \> 1 pack/week, seizures (all within the last 6 months) will be excluded from the study.
  • Participants with history of liver, intestinal or renal dysfunction, pregnancy or lactation, allergy against GTs, mangos, history of hepatitis B, C, or HIV, use of systemic antibiotics within 1 months of screening, participation in other interventional research study, intake of herbal dietary supplements.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Collaborative Agricultural Research Center

Prairie View, Texas, 77446, United States

Location

Related Publications (38)

  • Wang L, Athinarayanan S, Jiang G, Chalasani N, Zhang M, Liu W. Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition. Hepatology. 2015 Jan;61(1):119-28. doi: 10.1002/hep.27373. Epub 2014 Dec 15.

    PMID: 25123259BACKGROUND
  • Vishvanath L, Gupta RK. Contribution of adipogenesis to healthy adipose tissue expansion in obesity. J Clin Invest. 2019 Oct 1;129(10):4022-4031. doi: 10.1172/JCI129191.

    PMID: 31573549BACKGROUND
  • Ruiz-Canizales J, Dominguez-Avila JA, Wall-Medrano A, Ayala-Zavala JF, Gonzalez-Cordova AF, Vallejo-Cordoba B, Salazar-Lopez NJ, Gonzalez-Aguilar GA. Fiber and phenolic compounds contribution to the hepatoprotective effects of mango diets in rats fed high cholesterol/sodium cholate. Phytother Res. 2019 Nov;33(11):2996-3007. doi: 10.1002/ptr.6479. Epub 2019 Aug 16.

    PMID: 31418509BACKGROUND
  • Pulido-Mateos EC, Lessard-Lord J, Guyonnet D, Desjardins Y, Roy D. Comprehensive analysis of the metabolic and genomic features of tannin transforming Lactiplantibacillus plantarum strains. Sci Rep. 2022 Dec 27;12(1):22406. doi: 10.1038/s41598-022-26005-4.

    PMID: 36575241BACKGROUND
  • Pett KD, Alex PG, Weisfuss C, Sandhu A, Burton-Freeman B, Edirisinghe I. Mango Consumption Is Associated with Increased Insulin Sensitivity in Participants with Overweight/Obesity and Chronic Low-Grade Inflammation. Nutrients. 2025 Jan 29;17(3):490. doi: 10.3390/nu17030490.

    PMID: 39940348BACKGROUND
  • Partridge SR, Redfern J. Strategies to Engage Adolescents in Digital Health Interventions for Obesity Prevention and Management. Healthcare (Basel). 2018 Jun 21;6(3):70. doi: 10.3390/healthcare6030070.

    PMID: 29933550BACKGROUND
  • Nouri M, Shateri Z, Faghih S. The relationship between intake of fruits, vegetables and dairy products with overweight and obesity in a large sample in Iran: Findings of STEPS 2016. Front Nutr. 2023 Jan 17;9:1082976. doi: 10.3389/fnut.2022.1082976. eCollection 2022.

    PMID: 36733471BACKGROUND
  • Na L, Zhang Q, Jiang S, Du S, Zhang W, Li Y, Sun C, Niu Y. Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial. Sci Rep. 2015 May 19;5:10344. doi: 10.1038/srep10344.

    PMID: 25989216BACKGROUND
  • Muscolo A, Mariateresa O, Giulio T, Mariateresa R. Oxidative Stress: The Role of Antioxidant Phytochemicals in the Prevention and Treatment of Diseases. Int J Mol Sci. 2024 Mar 13;25(6):3264. doi: 10.3390/ijms25063264.

    PMID: 38542238BACKGROUND
  • Munkong, N., Ruxsanawet, K., Ariyabukalakorn, V., Mueangchang, W., Sangkham, S., Silangirn, P., Thim-uam, A., Naowaboot, J., Somparn, N., & Yoysungnoen, B. (2024). Hepatoprotective effects of Elaeagnus latifolia fruit extract against acetaminophen-induced hepatotoxicity in mice: Mechanistic insights. Journal of Functional Foods, 114, 106077. https://doi.org/10.1016/j.jff.2024.106077

    BACKGROUND
  • Molano L-AG, Vega-Abellaneda S, Manichanh C. GSR-DB: a manually curated and optimized taxonomical database for 16S rRNA amplicon analysis. mSystems. 2024 Feb 20;9(2):e0095023. doi: 10.1128/msystems.00950-23. Epub 2024 Jan 8.

    PMID: 38189256BACKGROUND
  • Metelcova T, Vankova M, Zamrazilova H, Hovhannisyan M, Stankova B, Tvrzicka E, Hill M, Hainer V, Vcelak J, Kunesova M. FADS1 gene polymorphism(s) and fatty acid composition of serum lipids in adolescents. Lipids. 2021 Sep;56(5):499-508. doi: 10.1002/lipd.12317. Epub 2021 Jun 30.

    PMID: 34189740BACKGROUND
  • Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, Beguinot F, Miele C. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci. 2019 May 13;20(9):2358. doi: 10.3390/ijms20092358.

    PMID: 31085992BACKGROUND
  • Liu AL, Xie HJ, Xie HY, Liu J, Yin J, Hu JS, Peng CY. Association between fat mass and obesity associated (FTO) gene rs9939609 A/T polymorphism and polycystic ovary syndrome: a systematic review and meta-analysis. BMC Med Genet. 2017 Aug 21;18(1):89. doi: 10.1186/s12881-017-0452-1.

    PMID: 28826396BACKGROUND
  • Lin PC, Lin WT, Yeh YH, Wung SF. Transcription Factor 7-Like 2 (TCF7L2) rs7903146 Polymorphism as a Risk Factor for Gestational Diabetes Mellitus: A Meta-Analysis. PLoS One. 2016 Apr 8;11(4):e0153044. doi: 10.1371/journal.pone.0153044. eCollection 2016.

    PMID: 27058589BACKGROUND
  • Liao J, Guo J, Niu Y, Fang T, Wang F, Fan Y. Flavonoids from Lycium barbarum leaves attenuate obesity through modulating glycolipid levels, oxidative stress, and gut bacterial composition in high-fat diet-fed mice. Front Nutr. 2022 Jul 28;9:972794. doi: 10.3389/fnut.2022.972794. eCollection 2022.

    PMID: 35967795BACKGROUND
  • Krenek KA, Barnes RC, Talcott ST. Phytochemical composition and effects of commercial enzymes on the hydrolysis of gallic acid glycosides in mango (Mangifera indica L. cv. 'Keitt') pulp. J Agric Food Chem. 2014 Oct 1;62(39):9515-21. doi: 10.1021/jf5031554. Epub 2014 Sep 18.

    PMID: 25185991BACKGROUND
  • Kim H, Castellon-Chicas MJ, Arbizu S, Talcott ST, Drury NL, Smith S, Mertens-Talcott SU. Mango (Mangifera indica L.) Polyphenols: Anti-Inflammatory Intestinal Microbial Health Benefits, and Associated Mechanisms of Actions. Molecules. 2021 May 6;26(9):2732. doi: 10.3390/molecules26092732.

    PMID: 34066494BACKGROUND
  • Kim H, Banerjee N, Barnes RC, Pfent CM, Talcott ST, Dashwood RH, Mertens-Talcott SU. Mango polyphenolics reduce inflammation in intestinal colitis-involvement of the miR-126/PI3K/AKT/mTOR axis in vitro and in vivo. Mol Carcinog. 2017 Jan;56(1):197-207. doi: 10.1002/mc.22484. Epub 2016 Apr 6.

    PMID: 27061150BACKGROUND
  • Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C375-C391. doi: 10.1152/ajpcell.00379.2020. Epub 2020 Dec 23.

    PMID: 33356944BACKGROUND
  • Imran M, Arshad MS, Butt MS, Kwon JH, Arshad MU, Sultan MT. Mangiferin: a natural miracle bioactive compound against lifestyle related disorders. Lipids Health Dis. 2017 May 2;16(1):84. doi: 10.1186/s12944-017-0449-y.

    PMID: 28464819BACKGROUND
  • Hui L, DelMonte T, Ranade K. Genotyping using the TaqMan assay. Curr Protoc Hum Genet. 2008 Jan;Chapter 2:Unit 2.10. doi: 10.1002/0471142905.hg0210s56.

    PMID: 18428424BACKGROUND
  • Hu XJ, Su MR, Cao BW, Ou FB, Yin RX, Luo AD. Relationship between the methylenetetrahydrofolate reductase (MTHFR) rs1801133 SNP and serum homocysteine levels of Zhuang hypertensive patients in the central region of Guangxi. Clin Hypertens. 2023 Oct 1;29(1):26. doi: 10.1186/s40885-023-00250-9.

    PMID: 37777810BACKGROUND
  • Holkem AT, Silva MPD, Favaro-Trindade CS. Probiotics and plant extracts: a promising synergy and delivery systems. Crit Rev Food Sci Nutr. 2023;63(28):9561-9579. doi: 10.1080/10408398.2022.2066623. Epub 2022 Apr 21.

    PMID: 35445611BACKGROUND
  • Hao, Y., Li, J., Wang, J., & Chen, Y. (2024). Mechanisms of Health Improvement by Lactiplantibacillus plantarum Based on Animal and Human Trials: A Review. Fermentation, 10(2), Article 2. https://doi.org/10.3390/fermentation10020073

    BACKGROUND
  • Hamza GM, Bergo VB, Mamaev S, Wojchowski DM, Toran P, Worsfold CR, Castaldi MP, Silva JC. Affinity-Bead Assisted Mass Spectrometry (Affi-BAMS): A Multiplexed Microarray Platform for Targeted Proteomics. Int J Mol Sci. 2020 Mar 16;21(6):2016. doi: 10.3390/ijms21062016.

    PMID: 32188029BACKGROUND
  • Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. NCHS Data Brief. 2020 Feb;(360):1-8.

    PMID: 32487284BACKGROUND
  • Gomes Natal DI, de Castro Moreira ME, Soares Miliao M, Dos Anjos Benjamin L, de Souza Dantas MI, Machado Rocha Ribeiro S, Stampini Duarte Martino H. Uba mango juices intake decreases adiposity and inflammation in high-fat diet-induced obese Wistar rats. Nutrition. 2016 Sep;32(9):1011-8. doi: 10.1016/j.nut.2016.02.008. Epub 2016 Mar 4.

    PMID: 27160499BACKGROUND
  • Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, Gude F, Garcia F, De Francisco A, Quintela AG. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013 Oct 16;13:47. doi: 10.1186/1472-6823-13-47.

    PMID: 24131857BACKGROUND
  • Fiedorova K, Radvansky M, Nemcova E, Grombirikova H, Bosak J, Cernochova M, Lexa M, Smajs D, Freiberger T. The Impact of DNA Extraction Methods on Stool Bacterial and Fungal Microbiota Community Recovery. Front Microbiol. 2019 Apr 17;10:821. doi: 10.3389/fmicb.2019.00821. eCollection 2019.

    PMID: 31057522BACKGROUND
  • Fang C, Kim H, Barnes RC, Talcott ST, Mertens-Talcott SU. Obesity-Associated Diseases Biomarkers Are Differently Modulated in Lean and Obese Individuals and Inversely Correlated to Plasma Polyphenolic Metabolites After 6 Weeks of Mango (Mangifera indica L.) Consumption. Mol Nutr Food Res. 2018 Jul;62(14):e1800129. doi: 10.1002/mnfr.201800129. Epub 2018 Jun 21.

    PMID: 29797702BACKGROUND
  • Dhawan D, Sharma S. Abdominal Obesity, Adipokines and Non-communicable Diseases. J Steroid Biochem Mol Biol. 2020 Oct;203:105737. doi: 10.1016/j.jsbmb.2020.105737. Epub 2020 Aug 18.

    PMID: 32818561BACKGROUND
  • Bratosiewicz-Wasik J, Liberski PP, Peplonska B, Styczynska M, Smolen-Dzirba J, Cycon M, Wasik TJ. Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene as risk factors for Alzheimer's disease. Neurosci Lett. 2018 Sep 25;684:86-90. doi: 10.1016/j.neulet.2018.07.010. Epub 2018 Jul 7.

    PMID: 29990559BACKGROUND
  • Bagheri S, Zolghadri S, Stanek A. Beneficial Effects of Anti-Inflammatory Diet in Modulating Gut Microbiota and Controlling Obesity. Nutrients. 2022 Sep 26;14(19):3985. doi: 10.3390/nu14193985.

    PMID: 36235638BACKGROUND
  • Antonio J, Knafo S, Kapoor R, Tartar JL. A fat mass and obesity-associated gene polymorphism influences fat mass in exercise-trained individuals. J Int Soc Sports Nutr. 2018 Aug 8;15(1):40. doi: 10.1186/s12970-018-0246-7.

    PMID: 30124167BACKGROUND
  • Al-Mnaser A, Dakheel M, Alkandari F, Woodward M. Polyphenolic phytochemicals as natural feed additives to control bacterial pathogens in the chicken gut. Arch Microbiol. 2022 Apr 12;204(5):253. doi: 10.1007/s00203-022-02862-5.

    PMID: 35412092BACKGROUND
  • Allali I, Arnold JW, Roach J, Cadenas MB, Butz N, Hassan HM, Koci M, Ballou A, Mendoza M, Ali R, Azcarate-Peril MA. A comparison of sequencing platforms and bioinformatics pipelines for compositional analysis of the gut microbiome. BMC Microbiol. 2017 Sep 13;17(1):194. doi: 10.1186/s12866-017-1101-8.

    PMID: 28903732BACKGROUND
  • Alkhatib A, Tsang C, Tiss A, Bahorun T, Arefanian H, Barake R, Khadir A, Tuomilehto J. Functional Foods and Lifestyle Approaches for Diabetes Prevention and Management. Nutrients. 2017 Dec 1;9(12):1310. doi: 10.3390/nu9121310.

    PMID: 29194424BACKGROUND

MeSH Terms

Conditions

Obesity

Interventions

Probiotics

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Dietary SupplementsFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Janet Antwi, Doctor of Philosophy

    Prairie View A&M University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

December 4, 2025

First Posted

April 1, 2026

Study Start

April 14, 2026

Primary Completion

June 1, 2026

Study Completion

June 1, 2026

Last Updated

June 9, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

De-identified individual participant data.

Shared Documents
ICF
Time Frame
After publication. No end date.
Access Criteria
Investigators who have been approved by IRB. All the de-identified data. Investigators will need to request it from the PI.
More information

Locations